Hematological changes associated with hepatitis by hepatitis E virus

Rahman, Mohammad Mizanur; Giti, Susane; Kabir, Shahidul; Rashid, M. Farzan

doi:10.3329/bsmmuj.v11i4.38619

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, in 2013, at Noakhali Police Training Centre, among 112 suspected cases, 76% were HEV [ 15 ], and two outbreaks were reported in northern Bangladesh, named Rajshahi city, during 2010 with HEV-1 (2162 suspected cases; from 62 probable cases, 58% were IgM anti-HEV positive) [ 16 ] and in 2017 [ 15 ]. There were two epidemics in the port city (Chattogram), one in 2012 affecting 698 army personnel confirmed by third-generation Enzyme Immune Assay [ 17 ]. Another large one in 2018 resulted in 2800 cases [ 18 ].…”

Section: History Of Hepatitis Ementioning

confidence: 99%

Hepatitis E Virus (HEV) Synopsis: General Aspects and Focus on Bangladesh

Aziz

Øverbø

Julin

et al. 2022

Viruses

View full text Add to dashboard Cite

HEV is the most common cause of acute hepatitis globally. This review summarizes the latest knowledge on the epidemiology, clinical characteristics, testing, and treatment of HEV infection. We also focused on Bangladesh to highlight the distinct challenges and the possible remedies. In low-income settings, the virus is mainly transmitted between people by fecal contamination of drinking water causing large outbreaks, and sporadic cases. The disease is usually mild and self-limiting acute hepatitis. Still, pregnant women and their offspring in low-income countries are at particular risk for severe disease, with up to 20% maternal mortality. Despite the high burden of the disease, HEV remains a relatively neglected virus, with detection hampered by costly tests and a lack of suitable treatments. Molecular PCR diagnostics, together with ELISA antibody tests, remain the preferred methods for diagnosis of HEV; however, rapid bedside diagnostics are available and could offer a practical alternative, especially in low-income countries. One vaccine (HEV 239) is only available in China and Pakistan, as efficacy against the other genotypes remains uncertain. The effectiveness trial conducted in Bangladesh might lead the way in gathering more efficacy data and could, together with improved surveillance and raised awareness, dramatically reduce the global burden of HEV.

show abstract

Section: History Of Hepatitis Ementioning

confidence: 99%